USA Falling prices are squeezing US generic and biosimilar manufacturers too hard, argues John Murphy III, President and CEO of the Association for Accessible Medicines (AAM). Generic prices have dropped an average of 7.7 percent a year over the past five years while medical inflation ran at 6.2 percent, and Murphy…
USA Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three decades of Amgen presence and USD six billion in cumulative investment. Seewoester discusses the rationale behind a further USD one…
USA Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt cell therapy manufacturing through a focused, scalable CDMO model. He highlights the company’s Princeton facility, flexible client partnerships, workforce development…
Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues. Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…
Global Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity is enormous, as is the potential impact for government coffers and patients. Can Europe maintain its position as the industry’s…
USA Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard Therapeutics, A Kyowa Kirin Company, discusses the critical role of newborn screening in identifying patients with metachromatic leukodystrophy (MLD), a…
USA Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US leadership, expanding pipeline, vertical integration, and focus on patient access. Salsi goes on to stresses that long-term biosimilar growth depends…
USA Pamela Gavin, CEO of the National Organization for Rare Disorders, discusses NORD’s origins in the advocacy movement that led to the Orphan Drug Act and its current mission to improve diagnosis, care, research, and policy for rare disease patients. She highlights the growing role of patient-led research, the need for…
USA Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024. Bringing together his experience building Astellas’s US presence and leading rare disease commercialization at Horizon, Camardo joined Immedica to lead…
USA Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning behind discontinuing the reni-cel cell therapy program in favor of lipid nanoparticle-delivered gene editing, and how EDIT-401, targeting severe hyperlipidemia,…
USA Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of the North American market, which accounts for nearly half of the company’s global revenue and a third of its workforce.…
USA Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine), and with XEOMIN® (incobotulinumtoxinA) continuing to anchor its portfolio, Paolillo reflects on how Merz…
See our Cookie Privacy Policy Here
